About this medicine
- Approved name
- GVK Biosciences
- International non-proprietary name (INN) or common name
- esomeprazole magnesium
- candesartan cilexetil
- nebivolol
- desloratadine
- donepezil
- repaglinide
- candesartan
- esomeprazole
- alendronic acid
- ropinirole
- cefpodoxime
- quetiapine
- trimetazidine
- bosentan
- tramadol
- paracetamol
- escitalopram
- trimetazidine hydrochloride
- entacapone
- valsartan
- hydrochlorothiazide
- donepezil hydrochloride
- ropinirole hydrochloride
- clopidogrel hydrochloride
- escitalopram oxalate
- metformin hydrochloride
- trimetazidine dihydrochloride
- rizatriptan benzoate
- metformin
- fluconazole
- eletriptan
- rizatriptan
- ebastine
- ibuprofen
- desmopressin
- aciclovir
- levetiracetam
- irbesartan
- venlafaxine
- ciprofloxacin
- cefpodoxime proxetil
- tacrolimus
- fexofenadine hydrochloride
- phenoxymethylpenicillin
- amlodipine besilate
- metoclopramide
- clopidogrel
- levodopa
- carbidopa
- entacapone
- atorvastatin
- telmisartan
- clindamycin hydrochloride
- metoclopramide hydrochloride
- clonazepam
- clobazam
- dexamethasone
- thiamine hydrochloride
- tramadol hydrochloride
- pioglitazone
- dipyridamole
- fexofenadine
- amlodipine
- pantoprazole
- hydrocortisone
About this procedure
- Current status
- European Commission final decision
- Reference number
- EMEA/H/A-31/1408
- Type
- Article 31 referrals
This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.
Key dates and outcomes
- CHMP opinion date
- 21/05/2015
- EC decision date
- 16/07/2015